178 related articles for article (PubMed ID: 23399737)
41. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.
Ueno Y; Tanaka S; Shimamoto M; Miyanaka Y; Hiyama T; Ito M; Kitadai Y; Yoshihara M; Sumii M; Chayama K
Dig Dis Sci; 2005 Jan; 50(1):163-6. PubMed ID: 15712655
[No Abstract] [Full Text] [Related]
42. Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab.
Moss AC; Kim KJ; Fernandez-Becker N; Cury D; Cheifetz AS
Dig Dis Sci; 2010 May; 55(5):1413-20. PubMed ID: 19533357
[TBL] [Abstract][Full Text] [Related]
43. Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience.
Magro F; Santos-Antunes J; Vilas-Boas F; Rodrigues-Pinto E; Coelho R; Ribeiro OS; Lopes S; Macedo G
J Crohns Colitis; 2014 Jul; 8(7):617-25. PubMed ID: 24332869
[TBL] [Abstract][Full Text] [Related]
44. Maintenance infliximab infusions forever?
Lee SD; Surawicz CM
Am J Gastroenterol; 2002 Nov; 97(11):2917-8. PubMed ID: 12425570
[No Abstract] [Full Text] [Related]
45. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
Lichtenstein GR
Am J Gastroenterol; 2005 Jul; 100(7):1433-5. PubMed ID: 15984959
[No Abstract] [Full Text] [Related]
46. Mortality associated with infliximab.
Lankarani KB
J Clin Gastroenterol; 2001 Sep; 33(3):255-6. PubMed ID: 11500623
[No Abstract] [Full Text] [Related]
47. Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
Fischer M; Campbell SC; Calley CSJ; Helper DJ; Chiorean MV; Fadda HM
Dig Dis Sci; 2017 Nov; 62(11):3131-3137. PubMed ID: 28986660
[TBL] [Abstract][Full Text] [Related]
48. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection.
del Valle García-Sánchez M; Gómez-Camacho F; Poyato-González A; Iglesias-Flores EM; de Dios-Vega JF; Sancho-Zapatero R
Inflamm Bowel Dis; 2004 Sep; 10(5):701-2. PubMed ID: 15472541
[No Abstract] [Full Text] [Related]
49. Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid, and azathioprine in a patient with Crohn's disease.
Itaba S; Iwasa T; Sadamoto Y; Nasu T; Misawa T; Inoue K; Shimokawa H; Nakamura K; Takayanagi R
Dig Dis Sci; 2007 Jun; 52(6):1438-41. PubMed ID: 17404870
[No Abstract] [Full Text] [Related]
50. [Fulminant acute hepatitis B after infliximab treatment in Crohn's disease].
Olfa H; Aroua G; Wissem M; Wafa BM; Hichem L; Nabil BC; Fethia B; Leila S
Tunis Med; 2014 May; 92(5):349-50. PubMed ID: 25504398
[No Abstract] [Full Text] [Related]
51. [Infliximab-induced hepatitis in a patient with Crohn's disease].
Soto-Fernández S; González-Carro P; De Pedro-Esteban A; Legaz-Huidobro ML; Pérez-Roldán F; Roncero García-Escribano O; Valbuena-González M; Ruiz-Carrillo F
Gastroenterol Hepatol; 2006 May; 29(5):321-2. PubMed ID: 16733041
[No Abstract] [Full Text] [Related]
52. [Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab].
Martín De Carpi J; Varea V
An Pediatr (Barc); 2009 Mar; 70(3):271-7. PubMed ID: 19409244
[TBL] [Abstract][Full Text] [Related]
53. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB
Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
[TBL] [Abstract][Full Text] [Related]
54. [Pneumocystis pneumonia during infliximab treatment for active Crohn's colitis].
Minnee RC; Stokkers P; Riemens SC; Hommes DW
Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2290-5. PubMed ID: 16240855
[TBL] [Abstract][Full Text] [Related]
55. [Top-down versus Step-Up: new strategies in the treatment of Crohn's disease].
Meier J; Sturm A
Z Gastroenterol; 2009 Feb; 47(2):240-2. PubMed ID: 19197829
[No Abstract] [Full Text] [Related]
56. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
Keil R; Wasserbauer M; Zádorová Z; Hajer J; Drastich P; Wohl P; Beneš M; Bojková M; Svoboda P; Konečný M; Falt P; Vaňásek T; Pešta M; Pešek F; Bouchner L; Koželuhová J; Novotný A; Bartůsková L; Špičák J
Scand J Gastroenterol; 2016 Sep; 51(9):1062-8. PubMed ID: 27002981
[TBL] [Abstract][Full Text] [Related]
57. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab.
Moss AC; Treister NS; Marsee DK; Cheifetz AS
Gastroenterology; 2007 Feb; 132(2):488, 829. PubMed ID: 17261307
[No Abstract] [Full Text] [Related]
58. Histoplasma epiglottitis in a patient with Crohn's disease maintained on infliximab, prednisone, and azathioprine.
Abou Zahr A; Saad Aldin E; Yunyongying P
Int J Infect Dis; 2013 Aug; 17(8):e650-2. PubMed ID: 23769453
[TBL] [Abstract][Full Text] [Related]
59. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time.
Loftus EV
Am J Gastroenterol; 2005 Jul; 100(7):1435-8. PubMed ID: 15984960
[No Abstract] [Full Text] [Related]
60. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
Sands BE; Kozarek R; Spainhour J; Barish CF; Becker S; Goldberg L; Katz S; Goldblum R; Harrigan R; Hilton D; Hanauer SB
Inflamm Bowel Dis; 2007 Jan; 13(1):2-11. PubMed ID: 17206633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
